China Resources Boya Bio-pharmaceutical Group Co (SZSE:300294) Cash And Cash Equivalents : ¥1,860 Mil (As of Mar. 2024)

China Resources Boya Bio-pharmaceutical Group Co Cash And Cash Equivalents Chart

China Resources Boya Bio-pharmaceutical Group Co Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Cash And Cash Equivalents		Get a 7-Day Free Trial					568.75	753.89	1,583.70	1,531.62	1,961.48

China Resources Boya Bio-pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															1,711.06	1,941.28	1,342.77	1,961.48	1,860.44

China Resources Boya Bio-pharmaceutical Group Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

China Resources Boya Bio-pharmaceutical Group Co  (SZSE:300294) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

China Resources Boya Bio-pharmaceutical Group Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of China Resources Boya Bio-pharmaceutical Group Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

China Resources Boya Bio-pharmaceutical Group Co (SZSE:300294) Business Description